Infant botulism linked to ByHeart formula ingredient supplier, Bloomberg News reports

Reuters
01/24
Infant botulism linked to ByHeart formula ingredient supplier, Bloomberg News reports

Jan 23 (Reuters) - U.S. Health officials found spores that can cause infant botulism at a supplier for formula-maker ByHeart during an investigation into an outbreak that has sickened dozens of babies, Bloomberg News reported on Friday, citing a document.

Infant botulism occurs when babies ingest spores of the bacteria Clostridium botulinum, which can grow in their immature digestive systems and produce the toxin.

Symptoms include constipation, poor feeding, loss of head control and difficulty in swallowing. In severe cases, infants can develop breathing problems.

U.S. Food and Drug Administration inspectors had found sanitation issues at some of ByHeart's factories over the last few years, and it had been unclear whether it was those conditions or an ingredient from an outside supplier that was the source of the contamination, the Bloomberg report said.

The document did not identify the contaminated ingredient or its maker, the report added.

As of December 17, 2025, an outbreak of the illness had sickened 51 infants across 19 states, according to the Centers for Disease Control and Prevention.

ByHeart claimed to have made the "closest to breast milk" formula with organic ingredients, the report added.

ByHeart initially recalled certain lots of its formula, in November. Three days later, it expanded the recall to include all its infant formula products.

The recall covered both cans and single-serve stick packs.

The FDA sent warning letters to four major retailers including Walmart WMT.O, Target TGT.N, Kroger KR.N and Albertsons ACI.N last month for continuing to sell baby formula linked to infant botulism, even after the products were recalled.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Alan Barona)

((siddhi.mahatole@thomsonreuters.com;))

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10